Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: J Neurooncol. 2014 Jul 2;119(3):503–512. doi: 10.1007/s11060-014-1495-1

Table 2.

Recurrent glioblastoma phase III trials—level 1 evidence

Study (reference) Number of patients per treatment arm Treatment PFS OS Comments
Enzastaurin versus lomustine in glioblastoma [72] 174 versus 92 Enzastaurin versus lomustine 1.5 versus 1.6 months 6.6 versus 7.1 months Enzastaurin did not have superior efficacy compared with lomustine in recurrent GBM
REGAL [67] 131 versus 65 versus 129 Cediranib versus lomustine versus cediranib/lomustine 92 versus 82 versus 125 days 8.0 versus 9.8 versus 9.4 months Cediranib alone or cediranib in combination with lomustine does not have superior efficacy compared with lomustine in recurrent GBM

PFS progression free survival, OS overall survival